Vascular interactions of prostaglandins with thromboxane in kidneys of rats developing hypertension.
We investigated the ability of the vasodilator prostaglandins E2 (PGE2) and I2 (PGI2) to counterbalance the vasoconstrictor action of thromboxane A2 (TxA2) in the rat renal vasculature during hypertension. In vivo measurements of renal blood flow (RBF) were made in 6-wk-old anesthetized spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats pretreated with indomethacin. The stable TxA2 agonist U-46619 was injected into the renal artery, and the magnitude and the kinetic parameters of the renal response were evaluated before and after continuous intrarenal infusion of a low dose of PGE2, viprostol (PGE2 analogue), PGI2, and iloprost (PGI2 analogue). The selected dose of vasodilator PGs did not affect arterial pressure and RBF. In the control period, the TxA2 agonist reduced RBF by 30% with a 90-s half time of recovery in both strains. Infusion of vasodilator PGs in young WKY significantly blunted the maximum vasoconstrictor effect of the TxA2 agonist and facilitated the recovery from vasoconstriction. In marked contrast, infusion of the vasodilator PGs in young SHR failed to affect the magnitude of the vasoconstrictor effect of the TxA2 agonist, although the recovery from vasoconstriction was facilitated as in WKY. On the other hand, infusion of bradykinin or dibutyryladenosine 3',5'-cyclic monophosphate (dibutyryl cAMP) blunted the TxA2-induced vasoconstriction to a similar degree in both strains.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Physiology, University of North Carolina at Chapel Hill 27599-7545.
C
C
Chatziantoniou
W J
WJ
Arendshorst
D000818:Animals; D001808:Blood Vessels / Q000378:metabolism; D001920:Bradykinin / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D006973:Hypertension / Q000503:physiopathology*; D011453:Prostaglandins / Q000494:pharmacology / Q000502:physiology*; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D012079:Renal Circulation / Q000187:drug effects; D013045:Species Specificity; D013928:Thromboxane A2 / Q000494:pharmacology / Q000502:physiology*; D014661:Vasoconstriction
D011453:Prostaglandins; D013928:Thromboxane A2; D003994:Bucladesine; D001920:Bradykinin